Blood cancer affects thousands of individuals each year, and despite impressive
early therapeutic advances, cure rates for most blood cancers have reached a plateau.
Not exact matches
Discovering New
Therapeutic Uses for Existing Molecules, announced in
early May, is the first major initiative from NIH's new National Center for
Advancing Translational Science (NCATS).
We're using this
advanced biomarker imaging endpoints as part of our way to detect whether the
therapeutic is having a positive effect
early in the trial.
Early diagnosis is important, as
therapeutic advances can lead to improved clinical outcome and patient benefit.